FILING ANALYSIS · THURSDAY, NOVEMBER 5
Starling Oncology, Inc. STLN — 8-K: Results of Operations and Financial Condition
positive
Starling Oncology reported a strong third quarter with revenue up 24.3% year over year and Adjusted EBITDA of $3.4 million, beating their outlook. They also affirmed their full-year 2026 guidance and expect continued growth into 2027.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →